Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.10 -0.9%	$22.72	$13.40 ▼ $25.88	$4.23B	0.7	2.19 million shs	1.59 million shs
ADMA ADMA Biologics	$17.67 +4.0%	$18.29	$13.50 ▼ $25.67	$4.22B	0.38	3.15 million shs	2.23 million shs
AKRO Akero Therapeutics	$48.68 -1.4%	$51.95	$21.34 ▼ $58.40	$3.89B	-0.28	1.42 million shs	392,100 shs
ALLO Allogene Therapeutics	$1.09 -1.4%	$1.25	$0.86 ▼ $3.78	$240.74M	0.35	4.41 million shs	2.54 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+2.97%	+12.28%	+15.19%	+64.48%
ADMA ADMA Biologics	0.00%	+2.85%	+1.55%	-15.85%	-3.19%
AKRO Akero Therapeutics	0.00%	-2.14%	-5.18%	+29.47%	+98.63%
ALLO Allogene Therapeutics	0.00%	+5.77%	-12.00%	+0.92%	-51.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.8942 of 5 stars	3.3	2.0	0.0	2.7	4.2	2.5
ADMA ADMA Biologics	4.4173 of 5 stars	3.7	3.0	0.0	4.1	2.5	3.1
AKRO Akero Therapeutics	3.9272 of 5 stars	3.5	2.0	4.7	3.2	0.8	0.0
ALLO Allogene Therapeutics	2.8639 of 5 stars	3.4	3.0	0.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	15.06% Upside
ADMA ADMA Biologics	3.33	Buy	$27.67	56.54% Upside
AKRO Akero Therapeutics	3.00	Buy	$81.57	67.56% Upside
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	678.29% Upside

Current Analyst Ratings Breakdown

Latest ADMA, ACAD, AKRO, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
8/4/2025	AKRO Akero Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
8/4/2025	AKRO Akero Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$76.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.42	$0.70 per share	35.94	$4.40 per share	5.70
ADMA ADMA Biologics	$426.45M	9.89	$0.56 per share	31.39	$1.48 per share	11.94
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
ALLO Allogene Therapeutics	$20K	12,036.99	N/A	N/A	$2.01 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	18.87	33.02	6.45	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
ADMA ADMA Biologics	$197.67M	$0.86	20.55	25.61	N/A	44.06%	41.01%	28.47%	11/6/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$2.00	N/A	N/A	N/A	N/A	-15.84%	-14.59%	N/A
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)

Latest ADMA, ACAD, AKRO, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.97	-$0.86	+$0.11	-$0.86	N/A	N/A
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/6/2025	Q2 2025	ADMA ADMA Biologics	$0.14	$0.15	+$0.01	$0.14	$121.77 million	$121.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
ADMA ADMA Biologics	0.21	5.33	2.78
AKRO Akero Therapeutics	0.02	12.66	12.66
ALLO Allogene Therapeutics	N/A	8.92	8.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ADMA ADMA Biologics	75.68%
AKRO Akero Therapeutics	N/A
ALLO Allogene Therapeutics	83.63%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
ADMA ADMA Biologics	3.70%
AKRO Akero Therapeutics	7.07%
ALLO Allogene Therapeutics	13.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	120.97 million	Optionable
ADMA ADMA Biologics	530	238.63 million	229.80 million	Optionable
AKRO Akero Therapeutics	30	79.99 million	74.33 million	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable

ADMA, ACAD, AKRO, and ALLO Headlines

Recent News About These Companies

Allogene Therapeutics (NASDAQ:ALLO) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

August 15 at 5:37 PM | marketbeat.com

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript

August 15 at 4:36 PM | msn.com

Allogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory Challenges

August 15 at 6:47 AM | msn.com

Allogene Therapeutics: Q2 Earnings Snapshot

August 14, 2025 | timesunion.comT

Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)

August 14, 2025 | msn.com

Allogene Narrows Loss in Fiscal Q2

August 14, 2025 | aol.comA

Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances

August 14, 2025 | msn.com

Allogene Therapeutics options imply 16.7% move in share price post-earnings

August 14, 2025 | msn.com

Allogene Q2 Cash Tops $300 Million

August 14, 2025 | aol.comA

Allogene Therapeutics: Important Catalysts Guided For Early 2026

August 14, 2025 | seekingalpha.com

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

August 14, 2025 | zacks.com

Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $8.44

August 14, 2025 | americanbankingnews.com

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

August 13, 2025 | globenewswire.com

Allogene Therapeutics Q2 2025 Earnings Preview

August 12, 2025 | msn.com

A Look at Allogene Therapeutics's Upcoming Earnings Report

August 12, 2025 | benzinga.com

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect

August 12, 2025 | finance.yahoo.com

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 12, 2025 | marketbeat.com

Allogene Therapeutics (ALLO) Receives a Buy from Robert W. Baird

August 9, 2025 | theglobeandmail.com

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

August 6, 2025 | globenewswire.com

JP Morgan Downgrades Allogene Therapeutics (ALLO)

August 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA, ACAD, AKRO, and ALLO Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.10 -0.23 (-0.92%)

Closing price 03:59 PM Eastern

Extended Trading

$25.06 -0.04 (-0.14%)

As of 04:10 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ADMA Biologics NASDAQ:ADMA

$17.67 +0.68 (+4.03%)

Closing price 03:59 PM Eastern

Extended Trading

$17.63 -0.04 (-0.25%)

As of 04:10 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Akero Therapeutics NASDAQ:AKRO

$48.68 -0.70 (-1.42%)

Closing price 03:59 PM Eastern

Extended Trading

$48.73 +0.05 (+0.09%)

As of 04:10 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics NASDAQ:ALLO

$1.08 -0.02 (-1.36%)

Closing price 03:59 PM Eastern

Extended Trading

$1.08 0.00 (0.00%)

As of 04:10 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time